Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
ARCALYST collaboration operating profit grew 114% year-over-year to $59.9 million.The following is a summary of the Kiniksa Pharmaceuticals International, Plc (KNSA) Q2 2024 Earnings Call Transcript:
以下是Kiniksa Pharmaceuticals International, Plc (KNSA) 2024年第二季度业绩会交流会议摘要：
Financial Performance:
金融业绩：
Kiniksa reported Q2 2024 total revenue of $108.6 million, including $103.4 million from ARCALYST, reflecting a 90% year-over-year growth.
Net loss for Q2 2024 was $3.9 million compared to net income of $15 million in Q2 2023.
ARCALYST collaboration operating profit grew 114% year-over-year to $59.9 million.
Anticipate a full year 2024 net sales guidance adjustment to $405 million to $415 million.
Kiniksa报告2024年第二季度总营业收入为10860万美元，包括来自ARCALYSt的10340万美元，同比增长90%。
2024年Q2净亏损为390万美元，而2023年Q2净利润为1500万美元。
ARCALYSt合作伙伴营业利润同比增长114%至5990万美元。
预计全年2024年净销售业绩指引为40500万-41500万美元。
Business Progress:
业务进展：
Continued strong commercial performance of ARCALYST in recurrent pericarditis, reaching an 11% penetration into the target patient population.
Invested in sales force expansion and partnerships including with the American Heart Association and Henrik Lundqvist for disease awareness.
Initiated a Phase 2b study of abiprubart in Sjögren's Disease, aiming to address the unmet medical needs in autoimmune diseases.
ARCALYSt在反复性心包炎方面持续表现强劲，目标患者群体渗透率达11%。
投资于拓展销售团队和合作伙伴，包括美国心脏协会和Henrik Lundqvist以提高疾病认知。
启动Sjögren's Disease的abiprubart二期20亿研究，旨在解决自身免疫性疾病的未满足医疗需求。
Opportunities:
机会：
Expanded ARCALYST treatment to a broader recurrence population, providing growth potential.
Enhanced marketing strategies and physician education to solidify ARCALYST as the standard therapy.
将ARCALYSt治疗拓展至更广泛的复发人群，提供增长潜力。
加强营销策略和医生教育，巩固ARCALYSt作为标准治疗。
Risks:
风险：
Acknowledges the gradual adaptation by prescribers and payers to recognize and treat recurrent pericarditis as a chronic condition could affect the pace of growth.
承认处方者和支付者逐渐适应认识和治疗反复性心包炎作为慢性病的步伐可能会影响增长速度。
More details: Kiniksa Pharmaceuticals International IR
更多详情请参阅Kiniksa Pharmaceuticals International IR。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。